Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Foghorn Therapeutics (FHTX) and Lilly will not advance FHD-909 or the Selective SMARCA2 degrader program. Foghorn will focus on its proprietary pipeline, including EP300 and CBP degraders, and a novel immunology program. The company expects to extend its cash runway into 2H 2029, following a 40% workforce reduction.
How this was made
The 30-second read
Why it matters
The announcement removes a potential late‑stage asset and reduces headcount, likely prompting a sell‑off as investors reassess the company's growth trajectory.
Market read
Primary biotech news with direct impact on FHTX valuation; limited broader market effect.
What to watch
The new EP300 and CBP degrader programs may still offer upside if they progress successfully.
Background
Foghorn Therapeutics (Nasdaq: FHTX) is a biotech focused on epigenetic degrader therapies. The company disclosed a strategic shift away from a collaborative SMARCA2 program with Eli Lilly.
Ticker impact
Foghorn Therapeutics announced it will not advance the FHD-909 program and will cut 40% of its workforce, impacting its pipeline and cash runway.
likely pressure as investors price in the loss of the SMARCA2 degrader program and higher execution risk.
Program termination removes a potential revenue source; the 40% layoff indicates cost cuts but also raises concerns about execution and future growth.
Market effects
May signal challenges for SMARCA2‑targeted therapeutics, potentially affecting peer biotech valuations.
Limited to US‑listed biotech sector.
Low, confined to specialty oncology and epigenetic drug development space.
Counterpoint
Cost cuts could extend cash runway, giving the company time to focus on higher‑potential pipeline assets.
Key entities
- companyFoghorn Therapeutics Inc.
Biotech developer of epigenetic degrader therapies.
- companyEli Lilly and Co.
Partner in the discontinued SMARCA2 program.